Agios Pharmaceuticals Inc (STU:8AP)
€ 43.2 -0.2 (-0.46%) Market Cap: 2.33 Bil Enterprise Value: 1.84 Bil PE Ratio: 0 PB Ratio: 3.37 GF Score: 35/100

Q3 2019 Agios Pharmaceuticals Inc Earnings Call Transcript

Oct 31, 2019 / 12:00PM GMT
Release Date Price: €26.73 (-4.12%)
Operator

Good morning and welcome to Agios' Third Quarter 2019 Conference Call. (Operator Instructions) Please be advised this call is being recorded at Agios' request.

I would now like to turn the call over to Kendra Adams, Vice President, External Communications and Investor Relations.

Kendra Adams
Agios Pharmaceuticals, Inc. - VP of External Communications & IR

Thank you, Kevin. Good morning, everyone, and welcome to Agios' Third Quarter 2019 Conference Call. You can access slides for today's call by going to the Investors section of our website, agios.com.

With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of U.S. Commercial and Global Marketing; and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Development. Dr. Scott Biller, our Chief Scientific Officer, will also be available for Q&A.

Before we get started, I would like to remind everyone that some of the statements we make on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot